Population Pharmacokinetic Modeling and Simulation of TQ-B3101 to Inform Dosing in Pediatric Patients With Solid Tumors

Background: TQ-B3101 is a novel kinase inhibitor currently in development for the treatment of advanced malignant solid tumor and relapsed or refractory ALK-positive anaplastic large cell lymphoma. Methods: A population pharmacokinetic model was developed using data collected from a Phase 1 study an...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Fen, Wu, Huali, Bo, Yunhai, Lu, Ye, Pan, Hong, Li, Su, Lu, Qin, Xie, Simin, Liao, Harry, Wang, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804354/
https://www.ncbi.nlm.nih.gov/pubmed/35115931
http://dx.doi.org/10.3389/fphar.2021.782518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804354/
https://www.ncbi.nlm.nih.gov/pubmed/35115931
http://dx.doi.org/10.3389/fphar.2021.782518

Ejemplares similares